市中型MRSA感染症治療薬の世界市場（～2026年）

• 英文タイトル：Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY00464 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は市中型MRSA感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（VAL-301、GLPG-1492、ソリスロマイシン、塩酸アコラフロキサシン、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別市中型MRSA感染症治療薬の競争状況、市場シェア ・世界の市中型MRSA感染症治療薬市場：種類別市場規模 2015年-2020年（VAL-301、GLPG-1492、ソリスロマイシン、塩酸アコラフロキサシン、その他） ・世界の市中型MRSA感染症治療薬市場：種類別市場規模予測 2021年-2026年（VAL-301、GLPG-1492、ソリスロマイシン、塩酸アコラフロキサシン、その他） ・世界の市中型MRSA感染症治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の市中型MRSA感染症治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の市中型MRSA感染症治療薬市場分析：米国、カナダ ・ヨーロッパの市中型MRSA感染症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの市中型MRSA感染症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の市中型MRSA感染症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの市中型MRSA感染症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Allergan Plc、Galapagos NV、Merck & Co Inc、Syntiron LLC、Valevia UK Ltd ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market
The global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Scope and Market Size
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market is segmented into
VAL-301
GLPG-1492
Solithromycin
Acorafloxacin Hydrochloride
Others

Segment by Application, the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market is segmented into
Hospital
Clinic
Others

Regional and Country-level Analysis
The Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share Analysis
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug business, the date to enter into the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug product introduction, recent developments, etc.

The major vendors covered:
Allergan Plc
Galapagos NV
Merck & Co Inc
Syntiron LLC
Valevia UK Ltd
…

レポート目次

---

1 Study Coverage
1.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Introduction
1.2 Market Segments
1.3 Key Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Growth Rate by Type
1.4.2 VAL-301
1.4.3 GLPG-1492
1.4.4 Solithromycin
1.4.5 Acorafloxacin Hydrochloride
1.4.6 Others
1.5 Market by Application
1.5.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size, Estimates and Forecasts
2.1.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue 2015-2026
2.1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales 2015-2026
2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Competitor Landscape by Players
3.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturers
3.1.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturers (2015-2020)
3.1.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturers
3.2.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturers (2015-2020)
3.2.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue in 2019
3.2.5 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Manufacturers
3.4 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturing Base Distribution, Product Types
3.4.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Type
3.4.3 Date of International Manufacturers Enter into Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Type (2015-2020)
4.1.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020)
4.1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2015-2020)
4.1.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Type (2021-2026)
4.2.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Application (2015-2020)
5.1.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020)
5.1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2015-2020)
5.1.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Application (2015-2020)
5.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Country
6.1.1 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country
6.1.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Type
6.3 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Country
7.1.1 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country
7.1.2 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Type
7.3 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Region
8.1.1 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region
8.1.2 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Type
8.3 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Country
9.1.1 Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country
9.1.2 Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Type
9.3 Central & South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Country
10.1.1 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country
10.1.2 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Type
10.3 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Allergan Plc
11.1.1 Allergan Plc Corporation Information
11.1.2 Allergan Plc Description and Business Overview
11.1.3 Allergan Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Products Offered
11.1.5 Allergan Plc Related Developments
11.2 Galapagos NV
11.2.1 Galapagos NV Corporation Information
11.2.2 Galapagos NV Description and Business Overview
11.2.3 Galapagos NV Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Products Offered
11.2.5 Galapagos NV Related Developments
11.3 Merck & Co Inc
11.3.1 Merck & Co Inc Corporation Information
11.3.2 Merck & Co Inc Description and Business Overview
11.3.3 Merck & Co Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Products Offered
11.3.5 Merck & Co Inc Related Developments
11.4 Syntiron LLC
11.4.1 Syntiron LLC Corporation Information
11.4.2 Syntiron LLC Description and Business Overview
11.4.3 Syntiron LLC Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Products Offered
11.4.5 Syntiron LLC Related Developments
11.5 Valevia UK Ltd
11.5.1 Valevia UK Ltd Corporation Information
11.5.2 Valevia UK Ltd Description and Business Overview
11.5.3 Valevia UK Ltd Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Products Offered
11.5.5 Valevia UK Ltd Related Developments
11.1 Allergan Plc
11.1.1 Allergan Plc Corporation Information
11.1.2 Allergan Plc Description and Business Overview
11.1.3 Allergan Plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Products Offered
11.1.5 Allergan Plc Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Estimates and Projections by Region
12.1.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Regions 2021-2026
12.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast (2021-2026)
12.2.1 North America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast (2021-2026)
12.2.2 North America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast (2021-2026)
12.2.3 North America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast (2021-2026)
12.3.2 Europe: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Segments
Table 2. Ranking of Global Top Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of VAL-301
Table 5. Major Manufacturers of GLPG-1492
Table 6. Major Manufacturers of Solithromycin
Table 7. Major Manufacturers of Acorafloxacin Hydrochloride
Table 8. Major Manufacturers of Others
Table 9. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug as of 2019)
Table 18. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price (2015-2020) (USD/Pcs)
Table 21. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Type
Table 23. Date of International Manufacturers Enter into Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Share by Type (2015-2020)
Table 27. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Share by Type (2015-2020)
Table 29. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Share by Application (2015-2020)
Table 32. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2015-2020)
Table 34. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2015-2020)
Table 38. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2015-2020)
Table 72. Allergan Plc Corporation Information
Table 73. Allergan Plc Description and Major Businesses
Table 74. Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Allergan Plc Product
Table 76. Allergan Plc Recent Development
Table 77. Galapagos NV Corporation Information
Table 78. Galapagos NV Description and Major Businesses
Table 79. Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Galapagos NV Product
Table 81. Galapagos NV Recent Development
Table 82. Merck & Co Inc Corporation Information
Table 83. Merck & Co Inc Description and Major Businesses
Table 84. Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Merck & Co Inc Product
Table 86. Merck & Co Inc Recent Development
Table 87. Syntiron LLC Corporation Information
Table 88. Syntiron LLC Description and Major Businesses
Table 89. Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Syntiron LLC Product
Table 91. Syntiron LLC Recent Development
Table 92. Valevia UK Ltd Corporation Information
Table 93. Valevia UK Ltd Description and Major Businesses
Table 94. Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Valevia UK Ltd Product
Table 96. Valevia UK Ltd Recent Development
Table 97. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 98. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share Forecast by Regions (2021-2026)
Table 99. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 100. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 101. North America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 102. North America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 103. Europe: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 104. Europe: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Asia Pacific: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 106. Asia Pacific: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 107. Latin America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 108. Latin America: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Middle East and Africa: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 110. Middle East and Africa: Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 112. Key Challenges
Table 113. Market Risks
Table 114. Main Points Interviewed from Key Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Players
Table 115. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Customers List
Table 116. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Distributors List
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product Picture
Figure 2. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type in 2020 & 2026
Figure 3. VAL-301 Product Picture
Figure 4. GLPG-1492 Product Picture
Figure 5. Solithromycin Product Picture
Figure 6. Acorafloxacin Hydrochloride Product Picture
Figure 7. Others Product Picture
Figure 8. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Report Years Considered
Figure 13. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size 2015-2026 (US$ Million)
Figure 14. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales 2015-2026 (K Pcs)
Figure 15. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region (2015-2020)
Figure 17. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region in 2019
Figure 18. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2015-2020)
Figure 19. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region in 2019
Figure 20. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue in 2019
Figure 22. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2015-2020)
Figure 24. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type in 2019
Figure 25. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type (2015-2020)
Figure 26. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type in 2019
Figure 27. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Price Range (2015-2020)
Figure 28. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2015-2020)
Figure 29. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application in 2019
Figure 30. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application (2015-2020)
Figure 31. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application in 2019
Figure 32. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country in 2019
Figure 35. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country in 2019
Figure 36. U.S. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Type in 2019
Figure 41. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Application in 2019
Figure 42. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country in 2019
Figure 45. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country in 2019
Figure 46. Germany Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Type in 2019
Figure 57. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Application in 2019
Figure 58. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region in 2019
Figure 61. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region in 2019
Figure 62. China Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Type in 2019
Figure 85. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Application in 2019
Figure 86. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country in 2019
Figure 89. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country in 2019
Figure 90. Mexico Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Type in 2019
Figure 97. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Application in 2019
Figure 98. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country in 2019
Figure 102. Turkey Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Type in 2019
Figure 109. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Application in 2019
Figure 110. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Dist

---